From Radiobiology to Radiation Oncology

Edited by:   Farzad Taghizadeh-Hesary, Sumel Ashique, Neeraj Mishra, Babak Behnam
Imprint:   Springer International Publishing AG
Country of Publication:   Switzerland
Dimensions:   Height: 235mm,  Width: 155mm, 
ISBN:   9783031957239
ISBN 10:   3031957237
Pages:   405
Publication Date:   29 August 2025
Audience:   Professional and scholarly ,  Undergraduate
Format:   Hardback
Publisher's Status:   Active

Dr. Farzad Taghizadeh-Hesary, M.D., is an Assistant Professor of Radiation Oncology at the Iran University of Medical Sciences. His research and clinical expertise lie at the intersection of radiation oncology, radiobiology, and cancer metabolism. Dr. Taghizadeh-Hesary's work focuses on integrating the tumor microenvironment and mitochondrial metabolism into cancer research and personalized radiotherapy. He has published over 90 peer-reviewed articles in high-impact journals and serves on the editorial boards of leading oncology journals. Dr. Taghizadeh-Hesary has received numerous awards, including the prestigious Razi Medical Science Research Prize. With a deep understanding of the complex interplay between radiation, tumor biology, and metabolic pathways, Dr. Taghizadeh-Hesary's work aims to develop innovative strategies for improving cancer treatment outcomes and enhancing the quality of life for patients. Sumel Ashique has been working as an assistant professor at the Department of Pharmaceutical Technology, Bharat Technology, West Bengal-711316, India. He has 5 years of teaching experience. He has achieved 80 publications of International and national accredited reputed journals. He has knowledge in drug delivery, nanotechnology and targeted treatment strategy. He is working as a potential reviewer for many well-known publishers (Elsevier, Springer, Dove Press, and Bentham Sc.). He has also 5 granted patents from IP and Australia, 20 published book chapters in Bentham, Springer, Elsevier, Bentham and Taylor & Francis. Currently, he is editing 14 books under CRC Press, Elsevier, Taylor and Francis, Wiley, Nova Science and Springer. He has published 80+ papers, including research, reviews, column articles, and an editorial in Scopus and WoS-indexed. He is serving as a guest editor in the JoVE journal (IF 1.2, Scopus & WOS indexed), Current Probiotics (Bentham Science) & Current Indian Science Journal. He is a potential reviewer in Elsevier, Springer, Taylor & Francis and Wiley journals for his expertise in the field of targeted drug delivery, nanotechnology, gut-microbiome and postbiotics. Currently, he is pursuing his PhD degree from Lovely Professional University, Punjab, India (NAAC A++) in the Pharmaceutical Science department. Dr. Neeraj Mishra has been a Professor at the Amity Institute of Pharmacy in Gwalior since July 2019. He brings approximately twenty-two years of teaching and research experience. He has supervised thirty M. Pharm students and two Ph.D. students. His publication record includes over 160 papers of international and national repute on topics such as novel drug delivery systems, oral delivery of synbiotics, localized drug delivery, and targeted and controlled drug delivery using nanocarriers and microparticles for treating breast, colon cancer, and neurodegenerative disorders. The total cumulative impact factor of his publications exceeds 500 (according to SCOPUS). He has authored more than 25 books and 45 book chapters published by Springer, Taylor and Francis, Elsevier, Bentham, and Wiley, among others. Additionally, he holds 3 international patents and 3 Indian patents. He received the ""Distinguished Professor Award"" in 2019 from DST-NSTMIS, SPAICS, Indore, and M.P., and the ""Distinguished Professor Award"" in 2021 from the Indian Pharmaceutical Association, MP State Branch, Indore. Dr. Mishra was also honored with the “Best Academician Award” at the Indian Pharmacy Graduate Association’s MP State International Conference held on May 6, 2023, at DAVV Auditorium, Indore India.  Dr. Babak Behnam (MD, PhD), is an academic researcher in the field of medical molecular biology and translational medicine at American University and Professor at the Floret Genomic Center. He earned his M.D. from Iran University of Medical Sciences (IUMS) in 1997 before specializing in genomic medicine, completing an M.Sc. in Molecular Medicine at the University of Sheffield and a Ph.D. in Human Genetics at University College London (UCL) in 2005. After his Ph.D., Dr. Behnam moved to the U.S., where he was awarded an NIH-based Ruth L. Kirschstein NRSA fellowship and completed four years of postdoctoral training at the University of Michigan and the University of Central Florida. His research focuses on molecular metastatic pathways, cancer biology, and mitochondrial genetics. At IUMS, he served as Associate Professor of Human Genetics, established and directed the medical genetics laboratory at OB/GYN and Children’s University Hospitals for seven years, and taught and mentored numerous students. Upon returning to the U.S., Dr. Behnam joined the NIH Undiagnosed Disease Program while completing an ABMGG-accredited clinical biochemical genetics fellowship at NHGRI, NIH. He later transitioned to Regulatory Affairs at NSF International, overseeing FDA submissions and compliance. As Co-Founder and Chief Scientific Officer (CSO) of Avicenna Biotech Research, he leads IP strategy and serves as a Medical Science Liaison (MSL). A prolific academic, Dr. Behnam has authored over 80 peer-reviewed publications, contributed to several chapters of five books, and holds editorial roles at MDPI Cancers and Frontiers. He also holds multiple patents in addiction therapies and cancer therapeutics.